Failing heart--medical aspectsTolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma
Section snippets
Patient population
From 1996 to 2000, a total of 487 patients began receiving open-label carvedilol for treatment of New York Heart Association (NYHA) functional Class I to Class IV systolic chronic heart failure. All patients attended a heart failure clinic at one institution and had received heart failure therapy for at least 3 months before beginning carvedilol therapy. The only exclusion criteria to attempting to introduce carvedilol were cardiogenic shock, intractable pulmonary and systemic edema, heart
Results
Of the 43 patients, 31 had COPD and 12 had asthma. The patients were predominantly men (88%) with moderately severe heart failure, as shown by the baseline demographics in Table I .
Lung function in heart failure
The interpretation of restrictive and obstructive defects observed with pulmonary function testing in patients with heart failure is difficult when concomitant airway disease is present.5, 6, 7 Reversible obstructive defects have been described in acute cardiac failure, whereas a restrictive defect with reduced DLCO is more typical of chronic congestive cardiac failure. The range of mechanisms proposed for the restrictive pattern includes respiratory muscle weakness, reduced lung volume caused
Conclusion
A large number of patients with heart failure and COPD can, in fact, tolerate carvedilol therapy and achieve substantial cardiac benefits from the treatment. The maximum dose of carvedilol achieved, tolerability, and improvements in cardiac function and survival were similar to those seen in our previously described patients who received open-label carvedilol for treatment of heart failure.8, 15 Despite the small number of patients in our study, asthma with significant reversibility (defined as
References (21)
- et al.
Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol
Am Heart J
(1999) - et al.
Effects of severity of long-standing congestive heart failure on pulmonary function
Respir Med
(1998) - et al.
Tolerability and efficacy of carvedilol in patients with New York Heart Association Class IV Heart Failure
J Am Coll Cardiol
(1999) - et al.
Diffusing capacity decreases after heart transplantation
Chest
(1993) - et al.
Utility of peak expiratory flow monitoring
Chest
(1998) - et al.
Adrenoceptors in airways smooth muscle
Pharm Ther
(1990) - et al.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
N Engl J Med
(1996) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
Lancet
(1997)- et al.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)a randomised trial
Lancet
(1999) - et al.
Effects of controlled-release metoprolol on total mortality, hospitalisations and well-being in patients with heart failurethe Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF)
JAMA
(2000)
Cited by (96)
Choosing among β-blockers in heart failure patients according to β-receptors’ location and functions in the cardiopulmonary system
2020, Pharmacological ResearchCitation Excerpt :β-blockers used to be considered – and are frequently still considered – contraindicated in patients with asthma and, to a lesser extent, in patients with COPD [34]. More recently, highly cardioselective β-blockers have proven to be safe both in asthma and COPD patients, while some concern still exists on the use of non-selective compounds, especially in asthma patients [35–37]. In particular, as regards asthma, ESC HF guidelines [1] report that β-blockers are only relatively contraindicated in asthma, apart from true severe asthma, however they should only be used under close medical supervision with consideration of the risk/benefit ratio.
Carvedilol attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling
2019, International ImmunopharmacologyAcutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival
2019, European Journal of Internal MedicineCitation Excerpt :Concerns regarding potential bronchoconstriction remain the main reason for underutilization of β-blockers in HF patients with comorbid COPD [20,54]. However, there is compelling evidence that β-blockers proven beneficial in HF, including carvedilol, are safe and well-tolerated in patients with COPD [55–58]. This study has both strengths and limitations.
Preoperative Evaluation
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionRole of beta-blockers in patients with COPD: Current perspective
2015, Drug Discovery TodayRisk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice
2013, American Journal of Medicine